On May 14th, 2021, ICER released a Draft Evidence Report entitled, “JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis.” Patients Rising Now responded to the request for comments on the report.
The comments noted that complex health conditions like atopic dermatitis have very different presentations and courses of action for different patients. In those cases, individualization of care and close coordination with clinicians is particularly important. Unfortunately, with its myopic, cost-fixated approach, ICER’s report will likely reduce access to therapies and impair the kind of patient-clinician care planning and coordination that are essential to treating this condition.
Click here to read Patients Rising Now’s full comments.